UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...

UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...

Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.

Key takeaways De prijs van bitcoin is gestaag gedaald, waardoor het op weg is naar het grootste maandelijkse verlies sinds juni 2022. Het daalde meer dan 19 procent in februari, het slechtste maandeli ...

Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.